“Diabetes should continue to have growth well above the company average.”

In context

“p therapy out there at the same time. And that growth is really driven by -- that's -- we think that's the new foundational technology sensing in the neuromod market and it's -- that growth is driven strictly by demand of these new products and pricing uplifts that came with them. Structural Heart, there's a lot of questions around the market there. And we're seeing consistent market growth as we've signaled in that high single digit and we're just really getting -- launching FX+ going from limited market at least a full market release, which is exciting. Plus the accumulation of all the data, smart, low risk, et cetera, is a real tailwind for us. Two businesses that had a particularly strong Q1 that I'm not sure is going to -- at that high level that throughout the year, one is Diabetes. Diabetes should continue to have growth well above the company average. But we're now annualizing the US launch of 780G. And so I can see diabetes in the teens last quarter. I'm not sure we are going to be able to sustain that the whole year. And CRM also had a really good quarter, some great -- we have a really nice product portfolio across the CRM, all the CRM segments. But we are not banking on CRM growing 8% every quarter. Those two -- there was nothing onetime about them, but just really strong execution. And I think across the company, I could just keep going on the list. There's just a lot of new products out there in the early stages. So overall, we feel good about the underlying fundamentals and where we are headed, and we're focused on delivering on our commitments and issuing guidance, issuing guidance sets us up for success. Vijay Kumar: That's he”